NasdaqGS - Delayed Quote USD

Kronos Bio, Inc. (KRON)

1.0000 +0.0200 (+2.04%)
At close: April 26 at 4:00 PM EDT
0.9810 -0.02 (-1.90%)
After hours: April 26 at 4:24 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Norbert W. Bischofberger Ph.D. President, CEO & Director 809.7k -- 1956
Mr. Joshua A. Kazam Co-Founder & Director 40k -- 1977
Ms. Sandra A. Gardiner Interim CFO & Principal Accounting Officer -- -- 1966
Dr. Margaux Bennett Ph.D. Vice President of Corporate Development & Investor Relations -- -- --
Ms. Allison Frisbee J.D. Senior Vice President of Corporate Operations & Legal -- -- 1983
Dr. Charles Lin Ph.D. Senior Vice President of Research & Development -- -- 1985
Dr. Elizabeth A. Olek D.O., M.P.H. Senior Vice President of Clinical Development -- -- 1965
Mr. Wes Trotter Ph.D. Senior Vice President of Drug Discovery & Pharmaceutical Development -- -- --
Ms. Rocio Martin Hoyos Senior Vice President of Corporate Strategy & Portfolio Management -- -- --

Kronos Bio, Inc.

1300 South El Camino Real
Suite 400
San Mateo, CA 94402
United States
(650) 781-5200 https://www.kronosbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
62

Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Corporate Governance

Kronos Bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Kronos Bio, Inc. Earnings Call

Related Tickers

TSBX Turnstone Biologics Corp.
2.7600
-4.83%
 
SNSE Sensei Biotherapeutics, Inc.
1.0200
-1.92%
 
TERN Terns Pharmaceuticals, Inc.
4.9100
+5.82%
 
IKNA Ikena Oncology, Inc.
1.3000
-0.76%
 
SLRN Acelyrin, Inc.
4.2400
0.00%
 
ACHL Achilles Therapeutics plc
0.7600
-2.69%
 
SPRB Spruce Biosciences, Inc.
0.7000
-0.14%
 
CYCC Cyclacel Pharmaceuticals, Inc.
1.5100
-5.63%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4700
-2.08%
 
NXTC NextCure, Inc.
1.3500
+4.65%